The Patent Finder

Alcediag

6 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
May 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (US 10,323,283) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Jul 16, 2027
    The maintenance fee for Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (US 11,873,531) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,771,953Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platform
In force
 · USPTO record
In forceUSPTO record
US 10,323,283Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
In force
 · USPTO record
In forceUSPTO record
US 10,851,420Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
In force
 · USPTO record
In forceUSPTO record
US 11,873,531Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
In force
 · USPTO record
In forceUSPTO record
US 12,084,719RNA editing as biomarkers for mood disorders test
In force
 · USPTO record
In forceUSPTO record
US 12,596,125Nano-Rheological Biomarkers for Early and Improved Follow-Up of Pathologies Associated to RBC Deformability Alteration
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 6: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 2 no status recorded

Showing 1 to 6 of 6, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/963,923Algorithm and an in Vitro Method Based on Rna Editing to Select Particular Effect Induced by Active CompoundsNov 29, 2024Pending
17/774,773Diagnosing of Mood Disorders Using Blood RNA Editing BiomarkersNov 9, 2020Pending
17/774,752Differential Diagnosis of Bipolar Disorder and Unipolar Depression by Blood Rna Editing BiomarkersNov 9, 2020Pending
16/083,492Algorithm and an in Vitro Method Based on Rna Editing to Select Particular Effect Induced by Active CompoundsMar 13, 2017Abandoned
15/445,901Feb 28, 2017No status recorded
14/297,933Jun 6, 2014No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited